Logo image of ANTX

AN2 THERAPEUTICS INC (ANTX) Stock Overview

NASDAQ:ANTX - US0373261058 - Common Stock

1.125 USD
-0.02 (-2.17%)
Last: 8/25/2025, 5:20:00 PM

ANTX Key Statistics, Chart & Performance

Key Statistics
52 Week High1.68
52 Week Low0.98
Market Cap30.75M
Shares27.33M
Float20.28M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-1.16
PEN/A
Fwd PEN/A
Earnings (Next)11-03 2025-11-03
IPO03-25 2022-03-25
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


ANTX short term performance overview.The bars show the price performance of ANTX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 2 4 6

ANTX long term performance overview.The bars show the price performance of ANTX in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of ANTX is 1.125 USD. In the past month the price increased by 5.61%.

AN2 THERAPEUTICS INC / ANTX Daily stock chart

ANTX Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 43.05 658.10B
JNJ JOHNSON & JOHNSON 17.84 429.67B
NVO NOVO-NORDISK A/S-SPONS ADR 14.52 250.34B
AZN ASTRAZENECA PLC-SPONS ADR 17.94 246.98B
NVS NOVARTIS AG-SPONSORED ADR 14.13 242.06B
MRK MERCK & CO. INC. 11.08 213.09B
PFE PFIZER INC 7.42 142.93B
SNY SANOFI-ADR 11.37 122.26B
BMY BRISTOL-MYERS SQUIBB CO 7 95.95B
GSK GSK PLC-SPON ADR 8.83 79.91B
ZTS ZOETIS INC 24.95 68.78B
TAK TAKEDA PHARMACEUTIC-SP ADR 51.97 47.59B

About ANTX

Company Profile

ANTX logo image AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The company is headquartered in Menlo Park, California and currently employs 22 full-time employees. The company went IPO on 2022-03-25. The firm is focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. Its initial candidate is epetraborole, which is a potential once-daily, oral treatment with a novel mechanism of action for patients with non-tuberculous mycobacterial (NTM) lung disease, a rare, chronic, and progressive infectious disease caused by bacteria known as mycobacteria, which leads to irreversible lung damage and can be fatal. Epetraborole is designed to produce broad-spectrum antimycobacterial activity through inhibition of an essential and universal step in bacterial protein synthesis. Epetraborole is an investigational, boron-containing, orally bioavailable, small molecule inhibitor of bacterial leucyl-tRNA synthetase (LeuRS), an enzyme that catalyzes the attachment of leucine to transfer RNA (tRNA), molecules, an essential step in protein synthesis.

Company Info

AN2 THERAPEUTICS INC

1800 El Camino Real, Suite D

Menlo Park CALIFORNIA 90501 US

CEO: Robert Corrigan

Employees: 22

ANTX Company Website

ANTX Investor Relations

Phone: 16503319090

AN2 THERAPEUTICS INC / ANTX FAQ

What is the stock price of AN2 THERAPEUTICS INC today?

The current stock price of ANTX is 1.125 USD. The price decreased by -2.17% in the last trading session.


What is the ticker symbol for AN2 THERAPEUTICS INC stock?

The exchange symbol of AN2 THERAPEUTICS INC is ANTX and it is listed on the Nasdaq exchange.


On which exchange is ANTX stock listed?

ANTX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for AN2 THERAPEUTICS INC stock?

8 analysts have analysed ANTX and the average price target is 1.53 USD. This implies a price increase of 36% is expected in the next year compared to the current price of 1.125. Check the AN2 THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is AN2 THERAPEUTICS INC worth?

AN2 THERAPEUTICS INC (ANTX) has a market capitalization of 30.75M USD. This makes ANTX a Nano Cap stock.


How many employees does AN2 THERAPEUTICS INC have?

AN2 THERAPEUTICS INC (ANTX) currently has 22 employees.


What are the support and resistance levels for AN2 THERAPEUTICS INC (ANTX) stock?

AN2 THERAPEUTICS INC (ANTX) has a support level at 1.06 and a resistance level at 1.14. Check the full technical report for a detailed analysis of ANTX support and resistance levels.


Should I buy AN2 THERAPEUTICS INC (ANTX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does AN2 THERAPEUTICS INC (ANTX) stock pay dividends?

ANTX does not pay a dividend.


When does AN2 THERAPEUTICS INC (ANTX) report earnings?

AN2 THERAPEUTICS INC (ANTX) will report earnings on 2025-11-03.


What is the Price/Earnings (PE) ratio of AN2 THERAPEUTICS INC (ANTX)?

AN2 THERAPEUTICS INC (ANTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.16).


What is the Short Interest ratio of AN2 THERAPEUTICS INC (ANTX) stock?

The outstanding short interest for AN2 THERAPEUTICS INC (ANTX) is 0.07% of its float. Check the ownership tab for more information on the ANTX short interest.


ANTX Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to ANTX. When comparing the yearly performance of all stocks, ANTX turns out to be only a medium performer in the overall market: it outperformed 46.98% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ANTX Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ANTX. No worries on liquidiy or solvency for ANTX as it has an excellent financial health rating, but there are worries on the profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ANTX Financial Highlights

Over the last trailing twelve months ANTX reported a non-GAAP Earnings per Share(EPS) of -1.16. The EPS increased by 48.67% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -49.3%
ROE -54.3%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%56.25%
Sales Q2Q%N/A
EPS 1Y (TTM)48.67%
Revenue 1Y (TTM)N/A

ANTX Forecast & Estimates

8 analysts have analysed ANTX and the average price target is 1.53 USD. This implies a price increase of 36% is expected in the next year compared to the current price of 1.125.


Analysts
Analysts47.5
Price Target1.53 (36%)
EPS Next Y37.18%
Revenue Next YearN/A

ANTX Ownership

Ownership
Inst Owners36.87%
Ins Owners9.45%
Short Float %0.07%
Short Ratio0.09